BioCentury
ARTICLE | Company News

Celyad amends CAR T deal

August 10, 2017 11:00 PM UTC

Celyad S.A. (Euronext:CYAD; NASDAQ:CYAD) amended a 2015 deal to increase its share of future revenues generated from chimeric antigen receptor (CAR) T assets partnered with Celdara Medical LLC (Lebanon, N.H.) and Dartmouth College (Hanover, N.H.).

Celyad said it decided to renegotiate a more front-loaded deal after initial data from the Phase I THINK trial of CAR-T NKR-2 (CYAD-01) to treat refractory solid and hematological tumors led to "increased confidence in the clinical opportunity" of the candidate. CAR-T NKR-2, which comprises autologous CAR T cells targeting killer cell lectin-like receptor subfamily K member 1 (NKG2D; KLRK1; CD314), is Celyad's lead CAR T cell product...